key: cord-0729504-afl2sj2l authors: Christensen, Jacob; O'Callaghan, Kevin; Sinclair, Holly; Hawke, Kate; Love, Amanda; Hajkowicz, Krispin; Stewart, Adam G. title: Risk factors, Treatment and Outcomes of Subacute Thyroiditis Secondary to COVID‐19: A Systematic Review date: 2021-06-17 journal: Intern Med J DOI: 10.1111/imj.15432 sha: 80868abf49330d01805d5604d9e3aa2a4de44d0f doc_id: 729504 cord_uid: afl2sj2l BACKGROUND: COVID‐19 is known to cause an acute respiratory illness, although clinical manifestations outside of the respiratory tract may occur. Early reports have identified SARS‐CoV‐2 as a cause of subacute thyroiditis (SAT). METHODS: A systematic review was conducted in accordance with the PRISMA guidelines. MEDLINE, Web of Science and PubMed databases were queried in February 2021 for studies from December 2019 to February 2021. MeSH search terms “COVID‐19”, “SARS‐CoV‐2” and “coronavirus” along with search terms “thyroiditis”, “thyrotoxicosis”, “thyroid” were used. Descriptive statistics for continuous variables and proportions for categorical variables were calculated. RESULTS: 15 publications reporting on 17 individual cases of COVID‐19 induced SAT were identified. Age ranged from 18 to 69 years old. The majority of the cases were female (14 of 17, 82%). The delay between onset of respiratory symptoms and diagnosis of SAT ranged from 5 to 49 days (mean, 26.5). Systemic inflammatory response syndrome (SIRS) related to viral infection was uncommonly reported at the time of SAT diagnosis. Thyroid ultrasonography frequently reported an enlarged hypoechoic thyroid with decreased vascularity and heterogenous echotexture. Elevated CRP was common at the time of SAT diagnosis, with results ranging from 4.5 to 176 mg/L (mean, 41 mg/L). Anti‐thyroid antibodies were frequently negative. SAT specific treatment included corticosteroids for 12/17 (70.5%) patients. Most return to normal thyroid status. CONCLUSION: COVID‐19 associated SAT may be difficult to identify in a timely manner due to potential absence of classic symptoms, as well as cross‐over of common clinical features between COVID‐19 and thyrotoxicosis. This article is protected by copyright. All rights reserved. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered after a cluster of patients with pneumonia of unknown cause were identified in Wuhan, China in December 2019 (1) . As of 13 April 2021, there have been almost 140 million global cases of SARS-CoV-2 infection with almost 3 million deaths. Coronavirus disease 2019 , caused by SARS-CoV-2 binding to angiotensin converting enzyme 2 (ACE2) on cell surfaces, is typically characterised by a respiratory tract infection ranging in severity from mild to life-threatening (2) . However, disorders of many organ systems have been associated with COVID-19. Thrombotic complications, myocardial dysfunction, acute kidney injury, hepatocellular injury, neurologic illnesses and dermatological complications have all been associated with COVID-19 (3) . Moreover, ACE2 has been shown to be expressed in many extrapulmonary tissues, including thyroid follicular cells (4) . There are numerous ways in which COVID-19 may affect thyroid function, and a few published case reports have described the development of new thyroid disease associated with COVID-19. Sub-acute thyroiditis (SAT) is an inflammatory disorder of the thyroid gland often causing thyrotoxicosis and is often associated with viral infection and lymphocytic infiltration (5) . Early case reports suggest that SAT may be associated with SARS-CoV-2, although further description of pathology, risk factors, clinical course and This article is protected by copyright. All rights reserved. outcomes are needed (6) . Here we performed a systematic review of all published cases of SAT associated with SARS-CoV-2 infection in order to better characterise this clinical phenomenon. A short narrative systematic review was conducted in accordance with PRISMA guidelines (7) . The Joanna Briggs Institute checklist for systematic reviews was used as a critical appraisal tool of evidence synthesis (8) . Articles were included in the review if they met the following criteria: (1) case report or case series of patients with confirmed SAT secondary to COVID-19; (2) MeSH search terms "COVID-19", "SARS-CoV-2" and "coronavirus" along with search terms "thyroiditis", "thyrotoxicosis", "thyroid" were used to extract relevant papers. Reference lists of key included articles were also examined for additional relevant papers. Conference abstracts and other unpublished accounts were excluded from our review. After a removal of duplicates a total of 268 articles were retained and the titles and abstracts were read to assess if the article met inclusion This article is protected by copyright. All rights reserved. criteria (Figure 1) . During the process, 235 articles did not meet inclusion criteria and were removed. The remaining 33 articles were read in full while applying the inclusion criteria and were assessed independently. During this process a further 18 articles were excluded. The remaining 15 manuscripts were identified as relevant to the research question. The full published manuscripts were reviewed by two authors (JC and AGS) to assess whether the appropriate clinical information in published texts were present. Extraction of data was undertaken independently by one author (JC). Extracted data included patient demographics (age, sex), clinical features, imaging findings, pathology data (CRP, thyroid function testing, antibodies), treatment and illness outcome (ICU admission, disease resolution). Descriptive statistics for continuous variables and proportions for categorical variables were calculated. At the time of publication, there have been 17 cases of reported COVID-19 associated SAT in 15 publications (9-21) ( Table 1) Viral infection appears to be the most common trigger for SAT (22, 23) . The most common viruses that are associated with SAT include adenovirus, influenza, mumps, enterovirus and coxsackievirus (24) . The incidence of SAT is higher in female compared to male sex (19.1 vs 4.1 per 100,000/year, respectively) (25) . SAT is clinically characterised by neck pain and thyroid tenderness and features of hyperthyroidism. Typically, elevated free T3 and T4 levels are seen in conjunction This article is protected by copyright. All rights reserved. with raised inflammatory markers and white blood cell count (24) . Anti-thyroid antibodies are typically absent. Early corticosteroid use for SAT may improve clinical outcomes (26) . The SARS-CoV-2 virus uses ACE2 combined with the transmembrane protease TMPRSS2 to enter and infect thyroid follicular cells (27) . Broadly speaking, it has been proposed that COVID-19 affects thyroid function indirectly (abnormal systemic inflammatory-immune responses) and directly (viral effect on gland). Indirect effects on the thyroid gland include hyperactivity of the Th1/Th17 immune responses that may play a role in triggering and sustaining inflammation of the gland (28, 29) . Indeed, thyroid ACE2 expression may be positively linked to inflammatory signatures and interferon response, thereby increasing the uptake of virus during acute illness (30) . Histopathological findings in the thyroid gland of patients with COVID-19 has demonstrated extensive injury and apoptosis to follicular epithelium and parafollicular cells (31) . Subacute thyroiditis appears to be the most common thyroid related clinical syndrome associated with COVID-19. Despite the viral cytopathic effects often seen on histological examination of thyroid tissue in patients with SAT, detection of culprit virus is usually unrewarding (32) . It has been proposed that a multitude of mechanisms contribute to the pathogenic pathway leading to thyroid follicular cell destruction in the context of recent or concurrent viral infection (22) ; this includes direct effect of the virus, autoimmune phenomena and abnormal systemic inflammatory responses (33) (34) (35) . In our systematic review, we aimed to identify key characteristics of this clinical phenomenon. The predominance of female patients is not surprising given that thyroid disease overall has a much higher prevalence rate in this population (36) . This article is protected by copyright. All rights reserved. patients had typical clinical features of SAT including neck tenderness and thyrotoxicosis. Meticulous clinical examination may be important to identify a tender thyroid as many patients may have neck tenderness secondary to upper respiratory tract inflammation. SAT can be seen with and without neck tenderness (22, 24) . Without neck tenderness, clinicians need to consider COVID-19-induced SAT as a cause for other, less localising signs. With regards to time of onset of SAT clinical features in relation to symptoms of SARS-CoV-2 infection, a wide range was observed. This may reflect the difference in pathophysiological mechanisms affecting the thyroid gland itself with regards to the direct viral cytopathic effect early in disease versus the inflammatory dysregulation that occurs later during the course of illness (28) . Interestingly, none of the patients had additional extrapulmonary end organ dysfunction related to COVID-19. In addition, SIRS, use of supplemental oxygen and ventilatory support was seen infrequently in this cohort. This may reflect a patient-level risk factor profile (e.g. female sex, genetic) or presence of confounding processes affecting thyroid function (e.g. ESS) in sicker patients. Anti-thyroid antibody testing appears to be unhelpful in this setting and has not been recommended routinely. A single measurement of TSH receptor antibodies to exclude Graves' disease would be a reasonable approach. Thyroid imaging, if deemed appropriate, shows features consistent with SAT; although in most settings of suspected SAT, reliance on clinical features and biochemical tests is usually all that is required. Indeed, imaging is not required for diagnosis and is not recommended during the infectious period due to potential risk of viral transmission to healthcare workers. A good response to corticosteroid treatment is usually observed with regards to SAT. An additional 28-day mortality benefit demonstrated with dexamethasone in hospitalised patients with COVID-19 in the RECOVERY trial (37) . Antithyroid medication have not proven to be effective during the thyrotoxic stage of illness, although were used in two cases of COVID-19 associated SAT (11, 12) . Most patients with adequate follow-up had documented return to a euthyroid state, consistent with the evolution of typical SAT. Routine assessment of thyroid function in the setting of COVID-19 has not been recommended in the COVID-19 clinical management guidelines by the World Health Organisation updated in 25 th This article is protected by copyright. All rights reserved. January 2021(38). The true prevalence of thyroid disease and thyroid function abnormalities in COVID-19 patients is largely unknown. The impact of COVID-19 on the thyroid gland can be heterogeneous and can include thyrotoxicosis, hypothyroidism and non-thyroidal illness syndrome (28) . Moreover, ESS, which is characterised by a decreased level of serum T3 and/or thyroxine (T4) without an increase in TSH, is often seen in critically ill patients and was noted in 27.5% of SARS-CoV-2 infected patients in one study (39) . Therefore, categorisation of a particular patient into specific disease state may prove to be difficult in some cases. Interestingly, based on a recently published meta-analysis pre-existing thyroid disease seems to be associated with enhanced risk of severe COVID-19 infection (40) . This finding may be explained by the role of thyroid hormones in regulating the innate immune response and the increased level of TNF-α and IL-6 observed in patients with thyroid disease (41) . SAT is emerging as a recognised complication of the pandemic disease COVID-19. This complication may be difficult to identify in a timely manner due to potential absence of classic symptoms (e.g. neck tenderness), as well as cross-over of common clinical features between COVID-19 and thyrotoxicosis. Features consistent with SAT including thyroid tenderness and tremor that are atypical for a systemic viral infection should prompt investigation for thyrotoxicosis. This short systematic review highlights the importance of considering SAT in those with COVID-19 and clinicians should consider requesting thyroid function tests in this setting. The prevalence and outcomes of SAT in COVID-19 requires further investigation. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. A Novel Coronavirus from Patients with Pneumonia in China Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19 Extrapulmonary manifestations of COVID-19 Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis Subacute, silent, and postpartum thyroiditis Endocrine Involvement in COVID-19: Mechanisms, Clinical Features, and Implications for Care The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Critical Appraisal Tools2020 A case of subacute thyroiditis associated with Covid-19 infection SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19 De Celis E. Thyrotoxic Crisis and COVID-19 Infection: An Extraordinary Case and Literature Review SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report Subacute Thyroiditis After Sars-COV-2 Infection Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic. Hormones (Athens) SARS-CoV-2-related atypical thyroiditis Subacute Thyroiditis in the Setting of Coronavirus Disease 2019 Subacute Thyroiditis in a Patient with Coronavirus Disease Subacute thyroiditis associated with COVID-19 Subacute thyroiditis as a presenting manifestation of COVID-19: a report of an exceedingly rare clinical entity Subacute Thyroiditis Associated with COVID-19 Viruses and thyroiditis: an update Thyroiditis: differential diagnosis and management Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study Comparison of the therapeutic effects of prednisolone and nonsteroidal anti-inflammatory drugs in patients with subacute thyroiditis Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study Impact of COVID-19 on the thyroid gland: an update Thyrotoxicosis in patients with COVID-19: the THYRCOV study Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues A potential role for integrins in host cell entry by SARS-CoV Failure in detection of Epstein-Barr virus and cytomegalovirus in specimen obtained by fine needle aspiration biopsy of thyroid in patients with subacute thyroiditis Subacute thyroiditis (de Quervain's) due to influenza A: presenting as fever of unknown origin (FUO) Subacute thyroiditis in the course of novel H1N1 influenza infection Clinical characteristics of 852 patients with subacute thyroiditis before treatment Thyroid disease in the elderly: sex-related differences in clinical expression Dexamethasone in Hospitalized Patients with Covid-19 Euthyroid Sick Syndrome in Patients With COVID-19 Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection Expression level and clinical significance of IL-2, IL-6 and TGFbeta in elderly patients with goiter and hyperthyroidism This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.